4//SEC Filing
Bedrosian Camille L 4
Accession 0000950170-25-036712
CIK 0001658551other
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 8:32 PM ET
Size
7.2 KB
Accession
0000950170-25-036712
Insider Transaction Report
Form 4
Bedrosian Camille L
Chief Medical Officer
Transactions
- Award
Common Stock
2025-03-06+68,420→ 206,800 total - Award
Stock Option (Right to Buy)
2025-03-06+102,630→ 102,630 totalExercise: $3.61Exp: 2035-03-05→ Common Stock (102,630 underlying)
Footnotes (2)
- [F1]The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F2]25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001326969
Filing Metadata
- Form type
- 4
- Filed
- Mar 9, 8:00 PM ET
- Accepted
- Mar 10, 8:32 PM ET
- Size
- 7.2 KB